This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall
by Zacks Equity Research
Allergan (AGN) lost a patent infringement lawsuit filed against companies trying to develop a generic version of its eye drug, Restasis, which is also its second bestselling drug.
Shire's New Formulation of Oncaspar Gets CHMP Recommendation
by Zacks Equity Research
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.
Keryx Focuses on Kidney Drug Auryxia Despite Generic Threat
by Zacks Equity Research
Keryx (KERX) is working on expanding its only marketed product, Auryxia's label.
Nektar's Lead Drugs Drive Growth, Partner Reliance a Woe
by Zacks Equity Research
Nektar (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.
Is Shire plc (SHPG) a Suitable Value Stock?
by Zacks Equity Research
Shire is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Supernus Drops SPN-810's Lower Dose Test in Phase III Trials
by Zacks Equity Research
Supernus (SUPN) decides to stop evaluating the lower dose option of SPN-810 for treatment of impulsive aggression. However, the company will carry on with the study of higher dose arm or placebo.
Neos Therapeutics ADHD Drug Adzenys Receives Approval in US
by Zacks Equity Research
Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.
Top Research Reports for Disney, Kraft Heinz & CVS Health
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Kraft Heinz (KHC) and CVS Health (CVS).
Alnylam Shares Plunge on Patient Death, Dosing Suspended
by Zacks Equity Research
Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient's death in a phase II study.
Roche (RHHBY) Hemophilia A Drug Granted Priority Review
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.
Shire Files Marketing Application for Lifitegrast in Europe
by Zacks Equity Research
Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.
Will Nektar's (NKTR) Candidates Enhance Growth in 2017?
by Zacks Equity Research
Nektar Therapeutics (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.
Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls
by Zacks Equity Research
Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View
by Zacks Equity Research
Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.
Allergan (AGN) Q2 Earnings & Sales Top, Restasis Sales Down
by Zacks Equity Research
Allergan plc (AGN) beat estimates for both earnings and sales in Q2. The company raised its 2017 outlook. Shares were down slightly in pre-market trading.
New Strong Sell Stocks for July 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Roche (RHHBY) Announces Positive Data on Hemophilia A Drug
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.
Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.
Alnylam Commences Phase III Study for Hemophilia Candidate
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) announced that it has commenced phase III ATLAS study for its candidate fitusiran.
Shire Completes NDA Filing for Hemophilia Drug with FDA
by Zacks Equity Research
Shire plc (SHPG) recently announced that it has filed an investigational new drug (IND) application with the FDA, seeking approval for its recombinant factor VIII (FVIII) gene therapy candidate, SHP654, for the treatment of patients with Hemophilia A.
KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline
by Zacks Equity Research
KemPharm, Inc. (KMPH) announced that it has strengthened its attention deficit hyperactivity disorder (ADHD) produg pipeline portfolio.
Kamada Withdraws Inhaled AAT Marketing Application in EU
by Zacks Equity Research
Kamada Ltd.'s (KMDA) decided to withdraw the marketing authorization application (MAA) for its inhaled formulation of Alpha-1 Antitrypsin (AAT) in the EU.
Shire (SHPG) Receives MAA Validation for Veyvondi by EMA
by Zacks Equity Research
Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.
Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US
by Zacks Equity Research
Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older
Could Shire PLC (SHPG) Be a Great Stock for Value Investors?
by Zacks Equity Research
Shire is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.